Systemic Anti-Cancer Therapy Regimen Library
LUNG NSCLC Metastatic - PACLItaxel Q1W
Treatment Overview
Cycle 1 - 7 days
Cycle 2 - 7 days
Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle 3 - 7 days
Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle 4 - 7 days
Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle 5 (and all further cycles) - 7 days
Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle details
Cycle 1 - 7 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| dexamethasone * | 8 mg | oral administration | 1 | |
| loratadine * | 10 mg | oral administration | 1 | |
| famotidine * | 20 mg | oral administration | 1 | |
| PACLItaxel * | 80 mg/m² | intravenous | 1 | 60 minutes |
| domperidone | 10 mg Three times daily | oral administration | 1 |
Cycle 2 - 7 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| dexamethasone * | 4 mg | oral administration | 1 | |
| loratadine * | 10 mg | oral administration | 1 | |
| famotidine * | 20 mg | oral administration | 1 | |
| PACLItaxel * | 80 mg/m² | intravenous | 1 | 60 minutes |
| domperidone | 10 mg Three times daily | oral administration | 1 |
Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle 3 - 7 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| ondansetron | 8 mg | oral administration | 1 | |
| loratadine * | 10 mg | oral administration | 1 | |
| famotidine * | 20 mg | oral administration | 1 | |
| PACLItaxel * | 80 mg/m² | intravenous | 1 | 60 minutes |
| domperidone | 10 mg Three times daily | oral administration | 1 |
Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle 4 - 7 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| ondansetron | 8 mg | oral administration | 1 | |
| loratadine * | 10 mg | oral administration | 1 | |
| PACLItaxel * | 80 mg/m² | intravenous | 1 | 60 minutes |
| domperidone | 10 mg Three times daily | oral administration | 1 |
Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Cycle 5 (and all further cycles) - 7 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| ondansetron | 8 mg | oral administration | 1 | |
| PACLItaxel * | 80 mg/m² | intravenous | 1 | 60 minutes |
| domperidone | 10 mg Three times daily | oral administration | 1 |
Tapering schedule of pre-medications is for patients who did not experience a hypersensitivity reaction to the previous dose of weekly PACLItaxel.
Full details
Cycle 1 - 7 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| dexamethasone * | 8 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion with food. |
|
| loratadine * | 10 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. |
|
| famotidine * | 20 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine. |
|
| PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
| domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
Cycle 2 - 7 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| dexamethasone * | 4 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion with food. |
|
| loratadine * | 10 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. |
|
| famotidine * | 20 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine. |
|
| PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
| domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
Cycle 3 - 7 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg. |
|
| loratadine * | 10 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. |
|
| famotidine * | 20 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine. |
|
| PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
| domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
Cycle 4 - 7 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg. |
|
| loratadine * | 10 mg | oral administration |
Instructions:
ONE hour prior to PACLItaxel infusion. |
|
| PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
| domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
Cycle 5 (and all further cycles) - 7 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg. |
|
| PACLItaxel * | 80 mg/m² | intravenous | 60 minutes |
Instructions:
Prepare solution in PVC-free bag and administer via polyethylene lined administration set with an in-line filter of 0.22 microns or less in size. Please carry out graded challenge as per institutional policy. |
| domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Low |
| Hypersensitivity / Infusion related reaction risk: | High - routine premedication recommended |
References
2. Novartis New Zealand Ltd. Paclitaxel Ebewe New Zealand Data Sheet 16 April 2020. https://www.medsafe.govt.nz/profs/Datasheet/p/PaclitaxelEbeweinj.pdf (Accessed 26 November 2020)
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.